Zoetis Inc. (ZTS) — ESG & Values Scores

Environment story

Zoetis demonstrates moderate environmental governance with disclosed sustainability commitments but lacks detailed Scope 1, 2, and 3 emissions quantification in available filings. The company operates 21 manufacturing sites globally and spent approximately $18 million on environmental compliance in 2025. Environmental risks are identified related to water supply disruptions, manufacturing disruptions from climate change, and regulatory scrutiny on animal health product environmental impacts. The company does not clearly disclose a Net-Zero target year or comprehensive Scope 3 supply-chain emissions accounting. Moderate deduction applied for undisclosed Scope 3 emissions and absence of disclosed Net-Zero target before 2045.

Criticisms on file

Undisclosed Scope 1 and Scope 2 emissions; no publicly stated Net-Zero target year or Scope 3 supply-chain emissions baseline disclosed in SEC filings reviewed.
Source: ZTS_10k.txt - Risk Factors section acknowledges increased regulatory scrutiny on animal health products' environmental impact but provides no quantitative baseline or decarbonization roadmap.
Climate change vulnerability: manufacturing processes dependent on clean water; increased frequency of natural disasters and adverse weather could disrupt manufacturing and supply chain.
Source: ZTS_10k.txt - Item 1A. Risk Factors: 'Climate change could have a material adverse impact on our and our customers' businesses.'
Livestock product environmental concerns: regulatory agencies showing increasing concern over impact of animal health products and livestock operations on environment; no detailed mitigation strategy disclosed.
Source: ZTS_10k.txt - Item 1A. Risk Factors: 'Furthermore, regulatory agencies are showing increasing concern over the impact of animal health products and livestock operations on the environment.'

Disclosed initiatives

Global Environmental Health and Safety (EHS) Policy

Established EHS performance standards for all sites; sites have injury prevention programs; tracks TIR and LTIR metrics monthly for manufacturing and R&D sites plus U.S. offices, field force, fleet and logistics.

Safety performance with TIR and LTIR rates lower than industry averages; demonstrates structured operational approach to occupational health but does not directly address carbon or environmental impact mitigation.
Environmental Compliance Expenditures

Incurred approximately $1 million in environmental-related capital expenditures and $17 million in other environmental-related expenditures in 2025 for compliance and cleanup of past industrial activities.

Indicates investment in environmental remediation; however, scale is modest relative to $9.5B revenue and does not clearly target operational decarbonization.
Sustainability Strategy and Chief Sustainability Officer

Executive Vice President, Corporate Affairs and Chief Sustainability Officer role established (Jeannette Ferran Astorga, since January 2022); Board exercises ultimate oversight over sustainability strategy and program.

Governance structure in place for sustainability; however, specific quantitative targets and timelines not disclosed in 10-K or proxy.

Social story

Zoetis demonstrates solid social governance practices with an engaged workforce (87% engagement rate in 2025), low voluntary attrition (7% in 2025), and comprehensive benefits including parental leave and fertility support. CEO-to-median-worker pay ratio not explicitly disclosed in available filings, preventing precise quantification but no evidence of egregious disparity flagged. Leadership diversity data partially disclosed (board gender composition visible; workforce diversity percentages not fully detailed in 10-K). The company reports 'some employees are members of unions, works councils, trade associations or are otherwise subject to collective bargaining agreements in particular jurisdictions' with 'a small number of employees in the U.S.' in unions—indicating low union density with no documented suppression activities or major strikes in past 24 months. Supply-chain ethics governance present but limited transparency on high-risk mineral sourcing (e.g., cobalt for diagnostics). No civil rights audit or formal modern slavery statement disclosed. Minor deductions for incomplete diversity reporting and limited human-rights due diligence transparency.

Criticisms on file

CEO-to-median-worker pay ratio not explicitly disclosed; unable to verify compliance with <200:1 rule or identify potential pay equity concerns.
Source: ZTS_10k.txt and ZTS_proxy.txt - Executive compensation tables present but median worker compensation not disclosed in available filings.
Workforce and leadership diversity percentages (women %, underrepresented racial/ethnic groups %) not quantitatively disclosed in SEC filings; board gender composition visible (4 of 12 nominees are women, 33%), but workforce-level DEI metrics opaque.
Source: ZTS_proxy.txt - Board demographics table shows gender composition; full workforce EEO-1 disclosure not provided in 10-K or proxy reviewed.
No formal modern slavery statement, forced-labor policy, or documented civil-rights audit disclosed; supply-chain human-rights due diligence not transparently detailed.
Source: ZTS_10k.txt - Manufacturing and supply chain section notes CMO vetting on quality and cost but no human-rights audit or slavery policy mentioned.
Supply-chain governance: Company selects CMOs based on quality, cost, capacity, and niche access but limited transparency on labor standards, conflict minerals, or living-wage commitments in global supply chain.
Source: ZTS_10k.txt - 'We select CMOs based on several factors: (i) their ability to reliably supply products or materials that meet our quality standards at an optimized cost; (ii) their access to niche products and technologies; (iii) capacity; and (iv) financial efficiency analyses.' No human-rights standards mentioned.

Disclosed initiatives

Colleague Engagement and Culture Programs

87% engagement rate in 2025 (sustained in high eighties for last five years); eight Colleague Resource Groups open to all employees; Open Door Policy encouraging ideas, concerns, questions without fear of retaliation; Core Beliefs framework emphasizing integrity and accountability.

Strong employee engagement signals healthy workplace culture; resource groups support inclusion; turnover reduction from 8% to 7% indicates effective retention.
Comprehensive Benefits and Compensation Programs

Flexible work arrangements, educational assistance, mental health support, pet care benefits, fully paid parental leave (all genders, same-sex partners), fertility and surrogacy benefits, enhanced childcare benefits; benefits vary by country and region.

Competitive compensation and benefits support employee well-being and work-life balance; demonstrates family-friendly and inclusive approach.
Talent Development and Leadership Programs

Talent development portal, mentoring programs, career planning resources, leadership development programs, performance management and training; R&D team recruits from universities and scientific associations.

Internal programs support career advancement and skill development; recruitment from academic institutions supports innovation pipeline.
Workplace Health and Safety

Global EHS Policy standards; injury prevention programs; monthly tracking of total injury rate (TIR) and lost time injury rate (LTIR) for manufacturing, R&D, U.S. offices, field force, fleet and logistics.

TIR and LTIR rates lower than industry averages; structured safety culture demonstrates commitment to employee protection.

Governance story

Zoetis demonstrates robust governance practices with 12 of 13 directors (92%) independent as of February 2026, exceeding the 75% threshold. The board includes diverse expertise across life sciences, manufacturing, M&A, digital technology, and global business. Single-class share structure (no dual-class voting) is confirmed. Board has adopted majority voting standard for director elections and mandatory retirement at age 75. However, annual lobbying expenditure is not disclosed in SEC filings, and specific lobbying targeting deregulation cannot be quantified. No active antitrust, consumer-safety, or financial-fraud proceedings disclosed in available filings. One shareholder proposal (written consent) rejected by board in 2026 proxy, with board arguing existing special-meeting call rights (25% ownership threshold) are sufficient. No evidence of shareholder lawsuits or activist challenges alleging governance failures. Minor deduction for non-disclosure of lobbying spend to facilitate transparency assessment.

Criticisms on file

Lobbying expenditure not disclosed in SEC filings; unable to verify compliance with rule restricting active lobbying for environmental deregulation or consumer-protection rollbacks.
Source: ZTS_10k.txt and ZTS_proxy.txt - No specific annual lobbying spend or policy position disclosures found in documents reviewed.
Shareholder proposal submitted in 2026 proxy (Item 5) requesting written-consent right; board unanimously recommends against, arguing existing special-meeting call right (25% threshold, one-year ownership) is adequate. Reflects board's resistance to low-threshold shareholder activism mechanism.
Source: ZTS_proxy.txt - Item 5: 'Shareholder Proposal to Permit Shareholder Action by Written Consent'; board argues written consent 'would circumvent the deliberative shareholder meeting process and serve to disenfranchise our shareholders.'
2025 shareholder proposal context: Multiple analyst downgrades and revenue forecast reductions led to stock price declines; Librela and Solensia (key OA pain medications) experienced 11% operational decline attributed to social media campaigns linking products to adverse effects; lawsuit filed regarding Librela. Proposal cites need for shareholder written-consent right to address underperformance.
Source: ZTS_proxy.txt - Item 5 supporting statement notes: 'The company's key OA pain medications, Librela (for dogs) and Solensia (for cats), experienced an 11% operational decline globally. This was largely attributed to negative perceptions and reports of adverse side effects amplified on social media...There have been social media campaigns linking Librela to severe autoimmune diseases and deaths in dogs, which generated negative publicity and a lawsuit.'

Disclosed initiatives

Board Independence and Diversity

12 of 13 directors independent; board includes former CEOs, CFOs, general counsels; gender diversity: 4 of 12 nominees are women (33%); racial/ethnic diversity: at least 2 Asian directors, 1 Black director represented; board tenure ranges 0-13 years; 4 new independent directors added in last four years.

High independence rate supports objective oversight; diversity of background and experience enhances decision-making; regular board refreshment reduces entrenchment risk.
Majority Voting Standard and Director Accountability

Amended bylaws require director election only if votes 'for' exceed votes 'against' in uncontested elections; every nominee must agree to tender resignation if failing to receive majority vote; Corporate Governance Committee recommends whether to accept resignation.

Accountability mechanism empowers shareholders to hold directors accountable; resignation requirement creates incentive for director performance.
Shareholder Rights to Call Special Meeting

2023 governance amendments permit shareholders owning combined 25% of outstanding shares continuously for at least one year to call special meeting; no solicitation clause requirement mandated by company.

Enables timely shareholder activism without awaiting annual meeting; 25% threshold is moderate (lower than many peers), supporting shareholder engagement.
Corporate Governance Principles and Committee Structure

Comprehensive Corporate Governance Principles published; Board committees include Audit, Compensation & Human Resources, Corporate Governance, Quality and Innovation, and Nominating & Corporate Governance; all committees consist entirely or substantially of independent directors.

Structured governance framework with specialized oversight; committee composition supports independence and expertise.
Board Oversight of Sustainability and Compliance

Board exercises ultimate oversight over sustainability strategy; Committees oversee animal welfare, human capital, pay equity, compliance, EHS, manufacturing quality, and public policy; Chief Sustainability Officer (EVP) role established.

Integrated ESG oversight across board and executive level; sustainability and compliance integrated into strategic governance.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Zoetis Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Zoetis Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)